Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Accumulated Expenses (2024 - 2025)

Historic Other Accumulated Expenses for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $88000.0.

  • Xilio Therapeutics' Other Accumulated Expenses fell 3623.19% to $88000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $88000.0, marking a year-over-year decrease of 3623.19%. This contributed to the annual value of $131000.0 for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Other Accumulated Expenses stood at $88000.0 for Q3 2025, which was down 3623.19% from $196000.0 recorded in Q2 2025.
  • Xilio Therapeutics' Other Accumulated Expenses' 5-year high stood at $196000.0 during Q2 2025, with a 5-year trough of $88000.0 in Q3 2025.